What is a Regulatory Dossier?
A regulatory dossier is a comprehensive collection of information about a
new pharmaceutical product. It is submitted to a Health Authority (like
CDSCO, FDA, or EMA) to seek approval for marketing the drug.
Historical Background
Different Formats: Every country/region had its own unique format and
content requirements for drug applications.
Duplication of Effort: Companies had to completely reformat and rewrite
large sections of their dossier for each new country
Slow Reviews: Reviewers at different agencies had to navigate unfamiliar
structures, leading to inefficient and slow approval processes.
Resource Intensive: This required massive amounts of paper, time, and
money for both industry and regulators.
Introducing the CTD
The Solution: ICH
The creation of a single, unified format for regulatory submissions—the
Common Technical Document (CTD).
What is the CTD?
The Common Technical Document (CTD) is a standardized format
for a new drug application dossier.
It defines the structure, content, and organization of the information to be
submitted to regulatory agencies.
The Core Principle
"One Dossier, Multiple Regions."
ORIGIN OF CTD
WAS OFFICIALLY SIGNED OFF IN NOVEMBER 2000, AT 5TH ICH
CONFERENCE; SAN DIEGO,CALIFORNIA
Q S
E M
M4: The Common Technical Document (CTD)
It is template for presenting data in the dossier
CTD IS A JOINT EFFORT OF 3 REGULATORY AGENCIES
[Link] Medicines Agency (EMEA, Europe 2. Food and Drug
Administration (FDA, USA ), ) and 3. Ministry of Health, Labour and Welfare
(MHLW,Japan). It has been adopted by several other countries including
Canada and Switzerland.
SIGNIFICANCE OF CTD
Avoid generating and compiling different registration dossiers
Common format will significantly reduce the time and resources
Simplifies review and approval processes.
Faster availability of new medicines
Facilitates exchange of information among regulatory authorities
Ease the preparation of electronic submissions
Makes lifecycle management and product updates more systematic.
Structure of the CTD: The Pyramid
The Five Modules
The CTD is organized into a five-module pyramid.
Module 1: Regional Administrative Info
Module 2: CTD Summaries
Module 3: Quality (CMC)
Module 4: Non-Clinical Study Reports
Module 5: Clinical Study Reports
Modules 2-5 are common across all regions. Only Module 1 is region-
specific.
Module 1: Regional Administrative Info
Contains region-specific documents. (e.g., Form 44 for India, FDA
Form 356h for USA).
Includes:
o Application forms and cover letters
o Product labeling and packaging information
o Patent details, fees, and legal documents
o Information required by the local authority (e.g., FDA Form
356h, EMA application form).
Note: Module 1 according to the region.
Module 2: CTD Summaries
2.1 CTD Table of Contents
2.2 CTD Introduction
2.3 Quality Overall Summary
2.4 Nonclinical Overview
2.5 Clinical Overview
2.6 Nonclinical Written and Tabulated Summary (Pharmacology,
Pharmacokinetics, Toxicology)
2.7 Clinical Summary (Biopharmaceutics and Associated Analytical
Methods, Clinical Pharmacology Studies, Clinical Efficacy, Clinical
Safety, Synopses of Individual Studies)
Module 3: Quality (CMC)
Describes Chemistry, Manufacturing, and Controls (CMC).
Includes data about:
Drug Substance: Manufacturer, structure, characterization,
impurities, stability.
Drug Product: Formulation, manufacturing process, specifications,
container closure.
Stability Studies: Long-term and accelerated data.
This module ensures product quality, safety, and consistency.
Module 4: Non-Clinical Study Reports
Contains results of animal studies and preclinical tests.
Divided into three main parts:
1. Pharmacology: Primary and secondary pharmacodynamic studies.
2. Pharmacokinetics (ADME): Absorption, Distribution, Metabolism,
Excretion.
3. Toxicology: Acute, sub-chronic, chronic, genotoxicity, reproductive,
and carcinogenicity studies.
This data ensures drug safety before human use.
Module 5: Clinical Study Reports
Contains human clinical trial data.
Includes:
Bioavailability and bioequivalence studies
Phase I, II, and III clinical trials
Safety and efficacy results
Post-marketing studies (Phase IV, if available)
This module proves that the product is safe and effective for human
use.
The sequence of M4 CTD for the Registration of
Pharmaceuticals for Human Use is
ICH
Sr. Module /
Guideline Description / Focus Area
No. Section
Code
General CTD Provides the overall structure and organization of
1 M4
guideline the CTD (modules, format, headings, etc.)
Covers Quality information — Chemistry,
2 M4Q Quality Manufacturing, and Controls (CMC) for drug
substance and product.
3 M4S Safety Covers Nonclinical / Preclinical studies —
pharmacology, pharmacokinetics, and toxicology
ICH
Sr. Module /
Guideline Description / Focus Area
No. Section
Code
data.
Covers Clinical studies — human
4 M4E Efficacy pharmacokinetics, pharmacodynamics, clinical
efficacy, and safety.
Limitations of CTD
Originally designed for paper-based submissions, requiring large
volumes.
Difficult to update or modify after submission.
Requires physical logistics for submission and archiving.
Time-consuming for both applicant and regulator.
Environmental concerns due to heavy paper usage.